MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acs.analchem.6c01173

Медицинская библиотека · Analytical chemistry · 2026

Flexible Dual-Apt Scaffolds Reveal gPD-L1-sEVs in Breast Cancer.

Qiu Xiaopei, Yang Fei, Guo Xinlin, Xu Peijun, Wang Xiaoxing, Lv Linxi, Xie Jie, Yu Zhengheng, Li Pingyun, Xiao Hui, Wang Tian, Wang Yongzhong, Gu Wei, Zhang Hong, Luo Yang

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The PD-1/PD-L1 blockade is a cornerstone of breast cancer immunotherapy, yet predictive biomarkers for immunotherapy outcomes remain scarce, restricting its clinical benefit. Glycosylated PD-L1 (gPD-L1) regulates tumor progression, immune suppression, and immune-checkpoint blockade (ICB) response, but it remains undetectable by conventional immunohistochemistry (IHC) due to glycan-mediated epitope shielding. This "detection blind spot" largely undermines current ICB biomarker prediction. To address this unmet clinical need, we developed an ultrasensitive CAP-g bioplatform with a novel CF/DPEDOT:PSS/Au nanoflexible scaffold. It integrates a dual-recognition-driven proximity cascade amplification for accurate gPD-L1 on small extracellular vesicle (gPD-L1-sEV) detection. We constructed this three-dimensional (3D) CF/DPEDOT:PSS/Au nanonetwork scaffold electrode, where π-π stacking synergistically minimizes charge-transfer resistance to improve electron transfer efficiency and maximizes the effective reaction area. Co-anchoring of a PD-L1 aptamer and a glycan probe further triggers hybridization chain reaction (HCR) for signal amplification, and this integrated design outperforms conventional electrochemical or immunological detection strategies. The CAP-g platform achieves an ultralow limit of detection (LOD) of 52 particles/mL, which is 1-2 orders of magnitude lower than existing gPD-L1-sEV or PD-L1-sEV detection methods, and a broad linear dynamic range of 103-108 particles/mL. Clinical validation in breast cancer patients and healthy controls showed robust discrimination between the two groups (P < 0.0001), with high specificity and reproducibility. This work overcomes the technical bottleneck of glycosylation interference in gPD-L1 detection, establishes a new liquid-biopsy paradigm for gPD-L1-sEV detection, and provides a reliable tool for predicting ICB efficacy in breast cancer, thus laying a critical foundation for personalized immunotherapy.

Для цитирования: Qiu Xiaopei, Yang Fei, Guo Xinlin, Xu Peijun, Wang Xiaoxing, Lv Linxi, Xie Jie, Yu Zhengheng, Li Pingyun, Xiao Hui, Wang Tian, Wang Yongzhong, Gu Wei, Zhang Hong, Luo Yang. Flexible Dual-Apt Scaffolds Reveal gPD-L1-sEVs in Breast Cancer.. Analytical chemistry. 2026. DOI: 10.1021/acs.analchem.6c01173.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.